Device Trial Radar · NCT00270946
Evaluation of Bilayered Cellular Matrix (OrCel) for the Treatment of Venous Ulcers
Last checked: Nov 20, 2026Latest source record: Dec 29, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
130
Actual
Start
Apr 2002
Primary completion
Not stated
Study completion Dec 2003
Sponsor
- Lead sponsor
- Ortec InternationalNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 29, 2005
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was designed to evaluate the clinical benefits and safety of OrCel in the treatment of venous ulcers. OrCel and standard care were compared to standard care alone. Standard care consisted of currently accepted compression therapy. Patients were treated for 12 weeks. Patients with healed ulcers were followed for an additional 12 weeks to assess durability of the healed wound.
Conditions
- Venous Leg Ulcer
- Venous Stasis Ulcer
Interventions
Bilayered Cellular Matrix (OrCel)Device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator assessment of wound healing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Terry Treadwell, MD
Montgomery, Alabama
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.